




Claims

1. A compound of Formula I:



wherein:



R^1 is H, -CN, halogen, C_1 - C_4 alkyl, -O-(C_3 - C_5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C_1 - C_4 alkyl), wherein when R^1 is not H, -CN or halogen, R^1 is optionally substituted with one or more halogen;

each R^2 is independently hydrogen, halogen or C_1 - C_4 alkyl;

R^3 is H or F;


R^{21} is H, halogen, C_1 - C_4 alkyl, C_3 - C_5 cycloalkyl or 4- to 6-membered heterocycle;

R^{22} is H, halogen or C_1 - C_2 alkyl;

R^{24} is -O-(C_1 - C_4 alkyl), -O-(C_1 - C_4 alkyl)-O-(C_1 - C_4 alkyl), -O-(C_3 - C_5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R^{24} is optionally substituted with one or more hydroxyl or halogen; and


R^{25} is H, halogen, C_1 - C_4 alkyl or C_3 - C_5 cycloalkyl, wherein R^{25} is optionally substituted with one or more halogen;

wherein the compound is not:





or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition characterized by dysregulation of a fatty acid synthase pathway, wherein the condition is a cancer.

2. Use of a compound of Formula I:



wherein:



R^1 is H, -CN, halogen, C_1 - C_4 alkyl, -O-(C_3 - C_5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C_1 - C_4 alkyl), wherein when R^1 is not H, -CN or halogen, R^1 is optionally substituted with one or more halogen;

each R^2 is independently hydrogen, halogen or C_1 - C_4 alkyl;

R³ is H or F;


R²¹ is H, halogen, C₁-C₄ alkyl, C₃-C₅ cycloalkyl or 4- to 6-membered heterocycle;

R²² is H, halogen or C₁-C₂ alkyl;

R²⁴ is -O-(C₁-C₄ alkyl), -O-(C₁-C₄ alkyl)-O-(C₁-C₄ alkyl), -O-(C₃-C₅ cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R²⁴ is optionally substituted with one or more hydroxyl or halogen; and

R²⁵ is H, halogen, C₁-C₄ alkyl or C₃-C₅ cycloalkyl, wherein R²⁵ is optionally substituted with one or more halogen;

wherein the compound is not:



or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a condition characterized by dysregulation of a fatty acid synthase pathway, wherein the condition is a cancer.

3. The use of claim 2, wherein the cancer is breast cancer; ovarian cancer; lung cancer; colon cancer; or pancreatic cancer.


4. The use of claim 2, wherein the cancer is a tumor derived from breast, lung, thyroid, lymph node, kidney, ureter, bladder, ovary, teste, prostate, bone, skeletal muscle, bone marrow, stomach, esophagus, small bowel, colon, rectum, pancreas, liver, smooth muscle, brain, spinal cord, nerves, ear, eye, nasopharynx, oropharynx, salivary gland, or heart tissue.

5. The use of claim 4, wherein the cancer is a tumor derived from breast, lung, prostate, colon, rectum, pancreas, liver, or brain tissue.


6. The use of any one of claims 2-5, wherein the medicament is for combined administration with an additional therapeutic agent, wherein the additional therapeutic agent is a cancer therapeutic agent selected from paclitaxel, doxorubicin, vincristine, actinomycin D, altretamine, asparaginase, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitozantrone, oxaliplatin, procarbazine, steroids, streptozocin, temozolomide, thioguanine, thiotepa, tomudex, topotecan, treosulfan, uracil-tegufur, vinblastine, and vindesine.

7. The use of claim 6, wherein the second therapeutic agent is a cancer therapeutic agent selected from paclitaxel, docetaxel, gemcitabine, and irinotecan.


8. The use of any one of claims 2-7, wherein in the compound of Formula (I) or the

pharmaceutically acceptable salt thereof, L-Ar is .

9. The use of any one of claims 2-7, wherein in the compound of Formula (I) or the

pharmaceutically acceptable salt thereof, L-Ar is .

10. The use of any one of claims 2-7, wherein in the compound of Formula (I) or the

pharmaceutically acceptable salt thereof, L-Ar is .

11. The use of any one of claims 2-10, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R³ is H.

12. The use of any one of claims 2-11, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R¹ is -CN or -O-(C₁-C₄ alkyl), wherein when R¹ is not -CN, R¹ is optionally substituted with one or more halogen; or R¹ is -CN; or R¹ is -O-(C₁-C₄ alkyl) optionally substituted with one or more halogen.

13. The use of any one of claims 2-12, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, each R² is hydrogen.

14. The use of any one of claims 2-13, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R²¹ is C₁-C₄ alkyl.






15. The use any one of claims 2-14, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R²² is H or C₁-C₂ alkyl.






16. The use of any one of claims 2-15, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R²⁴ is -O-(C₁-C₄ alkyl) optionally substituted with one or more hydroxyl or halogen; or R²⁴ is -O-(C₁-C₄ alkyl) optionally substituted with one or more hydroxyl.






17. The use of any one of claims 2-15, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R²⁴ is -O-(C₁-C₄ alkyl)-O-(C₁-C₄ alkyl), -O-(C₃-C₅ cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R²⁴ is substituted with one or more hydroxyl or halogen, or R²⁴ is -O-(C₁-C₄ alkyl) substituted with one or more hydroxyl.


18. The use of any one of claims 2-17, wherein in the compound of Formula (I) or the pharmaceutically acceptable salt thereof, R²⁵ is -CH₃.

19. The use of any one of claims 2-7, wherein the compound of Formula (I) has one of the following structures:







CC1=C(C(=C(C=C1)C2=C(C)C(=N2)OCCO)C(=O)N3CCc4ccc(C#N)cc4)C

21. The use of any one of claims 2-7, wherein the compound of Formula (I) is:

